CXorf61 is a target for T cell based immunotherapy of triple-negative breast cancer

Claudia Paret(University Medical Center of the Johannes Gutenberg University Mainz), Uğur Şahin(University Medical Center of the Johannes Gutenberg University Mainz)
Oncotarget
July 29, 2015
10.18632/oncotarget.4516
Cited by 81

Related Papers

mRNA-based therapeutics — developing a new class of drugs
|Nature Reviews Drug Discovery|2014|2.4k
COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses
|Nature|2020|2k
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
|Nature|2021|828
BNT162b vaccines protect rhesus macaques from SARS-CoV-2
|Nature|2021|735
Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells
|Blood|2006|605